Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644839 | 0.83 | CYP1A2 (0.48) | CYP1A2CYP2A6AHRBACE1KDM4E | |
| SCHEMBL2318276 | 0.77 | ESR1 (0.35) | CYP1A2 | |
| SCHEMBL756551 | 0.76 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL644419 | 0.76 | CYP2A6 (0.50) | CYP2A6AHRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8355321 | 0.74 | NOS1 (0.31) | — | |
| SCHEMBL646094 | 0.74 | CYP2A6 (0.48) | CYP1A2CYP2A6AHRBACE1KDM4E | |
| SCHEMBL2252898 | 0.74 | ALDH1A1 (0.48) | CYP2A6KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL645977 | 0.74 | CYP2A6 (0.48) | CYP1A2CYP2A6BACE1KDM4EALDH1A1 | |
| SCHEMBL1296866 | 0.74 | CYP1A2 (0.48) | CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL1921671 | 0.74 | ALDH1A1 (0.32) | CYP2A6ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | claimed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | claimed |
| EP-2914589-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - Science Park S.p.A. (IT) | 2015-09-09 | — | — | EP | claimed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | claimed |
| US-6235753-B1 | TUMOR NECROSIS FACTOR; AUTOIMMUNE DISEASES; ANTIALLERGENS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | claimed |
| EP-0279598-B1 | ARYLPIPERAZINYL-ALKYLENE-PHENYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1993-09-15 | — | — | EP | claimed |
| EP-0279598-A2 | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1988-08-24 | — | — | EP | claimed |
| US-20240231230-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | NISSAN CHEMICAL CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240201593-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | NISSAN CHEMICAL CORPORATION (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-118159910-A | Additive-containing silicon-containing resist underlayer film forming composition | 日产化学株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117940850-A | Composition for forming silicon-containing resist underlayer film, laminate using same, and method for producing semiconductor element | 日产化学株式会社 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024063044-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | 日産化学株式会社 | 2024-03-28 | — | — | WO | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0383635-A2 | Peptides having renin inhibitory activity their preparation and use | Sankyo Company Limited (JP) | 1990-08-22 | — | — | EP | disclosed |
| US-4891375-A | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1990-01-02 | — | — | US | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
| EP-0279598-A2 | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | CYP1A2 3132/4885CYP2A6 3823/4885AHR 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.